Alfasigma

Gender equality does not happen in a vacuum! Acceleration requires collaboration, determination, and collective action. Around the world, organizations and individuals are uniting to drive progress in key areas like women’s economic empowerment, leadership, and representation in STEM. Globally, women hold just 31.7% of senior leadership roles – and that’s not good enough. At Alfasigma, we’ve surpassed this number, but we’re still eager to accelerate our efforts and have more women contribute to our business. An inclusive environment only makes us better! #InternationalWomensDay #AccelerateAction #PharmaceuticalWithPassion   Source: World Economic Forum, Global Gender Gap 2024, Insight Report June 2024

Today is #RareDiseaseDay! Every rare disease tells a unique story, more than you can imagine. A disease is considered rare when it affects fewer than 1 in 2,000 people, but for those living with one, rarity does not mean invisibility. Patients with rare diseases face multiple challenges every day: 💡 Delayed diagnosis due to limited scientific knowledge and complex symptoms ⚕️ Difficult access to treatment and care, leading to inequalities 🔄 Misdiagnosis, as many rare diseases share symptoms with more common conditions 🌍 The need for global commitment to connect experts and drive innovation At Alfasigma, we believe that no disease is too rare to deserve attention. We are committed to addressing patients’ needs and innovating to create life-changing solutions. Together, we can do more. #PharmaceuticalsWithPassion #RareDiseaseDay2025 #RareDiseases Source: www.rarediseaseday.org

Wrapping Up an Inspiring ECCO 2025!  As ECCO 2025 comes to an end, we reflect on the insightful scientific discussions and meaningful exchanges that took place during the event, bringing us all together around the shared goal of improving the lives of people with IBD and gastrointestinal disorders. The congress was a valuable opportunity to strengthen collaboration within the scientific, healthcare and patient communities. #PharmaceuticalsWithPassion #ECCO2025 #UlcerativeColitis #IBD 

Alfasigma is proud to have supported #Rust2Dakar 2024, the charity rally organized by the humanitarian association Tavolo8 ODV to raise awareness and funds for cooperation projects benefiting the most vulnerable groups in West Africa. Marina Golinelli, Deputy Chairman of Alfasigma, took part in the rally as a member of the RustyPenguins team. This 6,023 km journey saw participants raise donations and helped spread the word about the projects and initiatives in West Africa by sharing updates on social media. At the end of this journey, the vehicles were donated to local communities in Africa to support Tavolo8’s humanitarian projects. Our car, "Sally," will continue to make important journeys at the Catholic mission of Suzana in Guinea-Bissau, enabling them to provide essential medical care to women and families in remote local communities. This initiative reflects our belief that even a small gesture can make a lasting impact by creating a strong, supportive, and collaborative community. #PharmaceuticalsWithPassion #WeAreAlfasigma

We are excited to be part of the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Berlin from February 19–22. Our participation in the congress and the new findings that will be presented, underline Alfasigma’s commitment to advancing care and improving the quality of life for people with gastrointestinal diseases such as Ulcerative Colitis. Alfasigma will also host a Satellite Symposium: 🗓 February 20, 19:00–20:00 📍 Room A4 💡 Topic: "Moderately Active UC in the Spotlight" https://lnkd.in/dqshTkf7 #PharmaceuticalsWithPassion #ECCO2025 #UlcerativeColitis #IBD

This week, we hosted our first Alfasigma Global Connect, live from the Opificio Golinelli, with thousands of colleagues joining us from around the Alfasigma world 🌍. It was a unique opportunity to connect as one team, focused on our shared priorities for 2025. 2024 was a truly transformational year – we achieved and learned a lot and increased our presence across the world. The strategy to continue our growth journey in 2025 is clear. Driven by passion for innovation, our teams are building the future by working side by side to provide better health and a better quality of life for people in three main therapeutic areas: gastroenterology, vascular, and rheumatology. The journey continues – and it’s us who Define the Future for Alfasigma, together 🚀. #PharmaceuticalsWithPassion #WeAreAlfasigma

As we approach the festive season and the end of another year, we want to thank all of you: our partners, colleagues, and community, for being part of our journey. We are excited to continue this journey with you in the year ahead. From all of us, warm wishes for joyful celebrations and an inspiring start to 2025! #PharmaceuticalsWithPassion #AlfasigmaHealthHub

Is it possible to travel with confidence while living with Ulcerative Colitis?  Travel is one of life’s most enriching experiences, and a diagnosis of Ulcerative Colitis should not prevent you from exploring the world and embracing new opportunities. While the symptoms of Ulcerative Colitis can present challenges, thoughtful planning and the right precautions enable many people to fully enjoy their travels, experiencing adventure, relaxation, and breathtaking destinations.   At Alfasigma, we are dedicated to helping individuals manage their health effectively, ensuring that travel remains an accessible and rewarding experience. 💬 What’s your next destination?  👉 Swipe through to discover essential tips for traveling with Ulcerative Colitis #AlfasigmaHealthHub #PharmaceuticalsWithPassion 

We’re happy to announce that Alfasigma is now member of PFMD (Patient Focused Medicines Development), a global collaborative coalition whose goal is to improve health by co-designing the future of healthcare for patients, WITH patients.   We’re eager to work together with key stakeholders worldwide, continuing our commitment to partnering with patients to improve their lives.

🚙 We’re proud to announce our support to #Rust2Dakar 2024, the charity rally aimed at helping the most fragile communities in West Africa! A proper on the road adventure that, following the legendary Paris-Dakar, crosses Morocco, Mauritania, Senegal and Guinea Bissau. The vehicles used by participants in the Rust2Dakar will be donated in Africa to support Tavolo 8's local projects, either being used in cooperation initiatives or to fund them. With enthusiasm and determination, Marina Golinelli, Deputy Chairman of Alfasigma, will join the race as member of the Rusty Penguins team, that will set off on December 26th on board of the car “Sally”. A journey in which learning to dare and working effectively as a team will be two fundamental elements to face the challenges of the path and reach the finish line on January 10. Rust2Dakar is organized by the humanitarian association Tavolo8 ODV with the goal of raising awareness and funds for cooperation projects aiding the most vulnerable groups in West Africa. For years, Alfasigma has been working alongside several organizations to carry out initiatives that help local communities grow and thrive, and this is another worthy chance to promote sustainable development and social inclusion. Why Rusty Penguins? Because just as they’re a symbol of adaptability and resilience in extreme environments, so this team perfectly embodies the spirit of the Rust2Dakar! This is how you can join and foster the race: 👉 Support Tavolo8 with a donation here: https://lnkd.in/dBNKAy-Z. Make sure to include the Rusty Penguins name and the team number 54 in the "Add a message to your donation" section 👉 Stay updated watching the Rust2Dakar Instagram Stories and interact by voting on the contents of the Rusty Penguins team. #PharmaceuticalsWithPassion #CSR